Evommune (EVMN) Return on Sales (2025 - 2026)
Evommune's (EVMN) quarterly Return on Sales came in at 0.14% in Q1 2026, down 9.0% year-on-year from 0.15% in Q1 2025, and down 113.95% on a QoQ basis from 0.06% in Q4 2025.
Evommune (EVMN) Return on Sales (2025 - 2026) Analysis & Trends
Evommune (EVMN) has 2 years of Return on Sales data on file, last reported at 0.14% in Q1 2026.
- On a quarterly basis, Return on Sales fell 9.0% year-over-year to 0.14% in Q1 2026; TTM through Mar 2026 was 0.14%, a N/A change from a year earlier, with the FY2025 full-year figure at 0.1%, down 1.0% from the prior year.
- Return on Sales for Q1 2026 stood at 0.14%, down from 0.06% in the prior quarter.
- Over the last five years, Return on Sales for EVMN reached as high as 0.02% in Q3 2025 and fell as low as 0.14% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | -0.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.14% |
| Dec 31, 2025 | -0.06% |
| Sep 30, 2025 | -0.02% |
| Mar 31, 2025 | -0.05% |